Olr649 inhibitors are a class of chemical compounds specifically designed to interact with and inhibit the activity of the Olr649 receptor, a member of the olfactory receptor family. Olfactory receptors, primarily known for their role in the detection of odor molecules, are G-protein-coupled receptors (GPCRs) embedded in the cell membranes of olfactory neurons. The Olr649 receptor, like others in its class, is characterized by a seven-transmembrane domain structure, which allows it to transduce extracellular signals through intracellular G-proteins, initiating a cascade of cellular responses. The inhibition of Olr649 is achieved through the binding of these inhibitors to the receptor, which either blocks the binding site for natural ligands or induces a conformational change that prevents signal transduction. This interaction can be highly specific, depending on the molecular structure of the inhibitor, which is designed to fit precisely into the receptor's binding site, thereby ensuring effective inhibition.
The development and study of Olr649 inhibitors involve a multidisciplinary approach, encompassing molecular biology, chemistry, and biophysics. Researchers employ various techniques to design these inhibitors, including computational modeling, structure-activity relationship (SAR) studies, and high-throughput screening of compound libraries. The efficacy of these inhibitors is often evaluated through in vitro assays, where their binding affinity and inhibitory potency are measured. Advanced techniques like X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are utilized to elucidate the detailed binding interactions between Olr649 inhibitors and the receptor, providing insights into the molecular basis of inhibition. Additionally, the study of Olr649 inhibitors contributes to a broader understanding of GPCR function and regulation, highlighting the intricate mechanisms by which these receptors control cellular responses. This research can pave the way for the development of more selective and potent inhibitors, enhancing our ability to manipulate olfactory receptor activity for scientific exploration.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
mTOR inhibitor, potentially disrupting proteins involved in cell growth and proliferation pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Src family kinases, potentially influencing proteins in cell signaling pathways. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, potentially impacting protein degradation and cell cycle regulation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibitor of EGFR and HER2, potentially disrupting proteins in associated signaling pathways. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $90.00 $210.00 $375.00 $740.00 $1225.00 | 4 | |
EGFR and HER2 inhibitor, potentially affecting proteins in these signaling pathways. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, potentially affecting proteins in ALK-driven signaling pathways. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, potentially disrupting proteins in cell signaling and growth pathways. | ||||||